Onkologie. 2023:17(2):123-126 | DOI: 10.36290/xon.2023.025

Long­‑term survival of a patient with disseminated adenocarcinoma of the ampulla of Vater: a complex therapeutic approach in metastases recurrence

Martin Gryc, Michal Eid
Interní hematologická a onkologická klinika LF MU a FN Brno

Adenocarcinoma of the ampulla of Vater is a rare but aggressive disease with a poor prognosis. While radical surgical resection is the standard treatment of choice, recurrence and metastatic dissemination remain common clinical challenges. Furthermore, there is no clear guideline consensus regarding adjuvant treatment. Precise histopathological characterization is paramount in terms of disease prognosis. We report a case of a patient who underwent a multimodal treatment for recurrent lung metastasis with a good clinical outcome.

Keywords: adenocarcinoma of the ampulla of Vater, adjuvant chemotherapy, metastasectomy.

Accepted: April 26, 2023; Published: April 27, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gryc M, Eid M. Long­‑term survival of a patient with disseminated adenocarcinoma of the ampulla of Vater: a complex therapeutic approach in metastases recurrence. Onkologie. 2023;17(2):123-126. doi: 10.36290/xon.2023.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rizzo A, Dadduzio V, Lombardi L, et al. Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. Curr Oncol. 2021 Sep 1;28(5):3393-3402. doi: 10.3390/curroncol28050293. PMID: 34590592; PMCID: PMC8482111. Go to original source... Go to PubMed...
    2. Al-Jumayli M, Batool A, Middiniti A, et al. Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience. J Oncol. 2019 May 2;2019:3293509. doi: 10.1155/2019/3293509. PMID: 31186632; PMCID: PMC6521487. Go to original source... Go to PubMed...
    3. Regalla DKR, Jacob R, Manne A, et al. Therapeutic options for ampullary carcinomas. A review. Oncol Rev. 2019 Sep 10;13(2):440. doi: 10.4081/oncol.2019.440. PMID: 31565197; PMCID: PMC6747019. Go to original source... Go to PubMed...
    4. Valsangkar NP, Ingkakul T, Correa-Gallego C, et al. Survival in ampullary cancer: potential role of different KRAS mutations. Surgery. 2015 Feb;157(2):260-8. doi: 10.1016/j.surg.2014.08.092. PMID: 25616942; PMCID: PMC4451831. Go to original source... Go to PubMed...
    5. Klein F, Jacob D, Bahra M, et al. Prognostic Factors for Long­‑Term Survival in Patients with Ampullary Carcinoma: The Results of a 15-Year Observation Period after Pancreaticoduodenectomy. HPB Surgery. 2014;(8):970234. Go to original source... Go to PubMed...
    6. Westgaard A, Tafjord S, Farstad IN, et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer. 2008;8:170. Go to original source... Go to PubMed...
    7. Bhatia S, Miller RC, Haddock MG, et al. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):514-9. doi: 10.1016/j.ijrobp.2006. 04. 018. Epub 2006 Jul 25. PMID: 16863684. Go to original source...
    8. Sikora SS, Balachandran P, Dimri K, et al. Adjuvant chemo­‑radiotherapy in ampullary cancers. Eur J Surg Oncol. 2005 Mar;31(2):158-163. doi: 10.1016/j.ejso.2004. 08. 013. PMID: 15698732. Go to original source...
    9. Saedon M, Maroulis I, Brooks A, et al. Metastasectomy of pancreatic and periampullary adenocarcinoma to solid organ: The current evidence. J BUON. 2018 Nov-Dec;23(6):1648-1654. PMID: 30610789. Go to PubMed...
    10. Pih GY, Kim DK, Park KM, et al. Bilateral lung metastasectomy in carcinoma of the ampulla of Vater. Thorac Cancer. 2017 Mar;8(2):124-127. doi: 10.1111/1759-7714.12418. Epub 2017 Feb 7. PMID: 28168842; PMCID: PMC5334294. Go to original source... Go to PubMed...
    11. Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. World J Gastroenterol. 2017 Mar 14;23(10):1872-1880. doi: 10.3748/wjg.v23.i10.1872. PMID: 28348494; PMCID: PMC5352929. Go to original source... Go to PubMed...
    12. Deeb A, Haque SU, Olowokure O. Pulmonary metastases in pancreatic cancer, is there a survival influence? J Gastrointest Oncol. 2015 Jun;6(3):E48-51. doi: 10.3978/j.issn.2078-6891.2014.114. PMID: 26029466; PMCID: PMC4397254. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.